甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床分析  

Clinical Analysis of Apatinib Mesylate in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：刘凯[1] 郭天利[1] 庞慧[1] 李春艳[1] 唐东霞[1] LIU Kai;GUO Tian-li;PANG Hui(The Second Department of Oncology,Jiaozuo Second People’s Hospital,Jiaozuo,Henan,454001, China)

机构地区：[1]焦作市第二人民医院肿瘤内科二区

出　　处：《黑龙江医学》2019年第5期431-432,共2页Heilongjiang Medical Journal

摘　　要：目的分析采用甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床疗效。方法随机选取焦作市第二人民医院80例于2015年10月—2017年11月间收治的晚期非小细胞肺癌患者作为研究对象,按入院先后顺序将患者分为研究组和对比组,每组各40例。给予研究组在对比组的基础上增加甲磺酸阿帕替尼片治疗,给予对比组常规化疗治疗,对比两组临床疗效。结果研究组总有效率(87.50%)明显高于对比组(65.00%),研究组药物安全性明显高于对比组,且相关血清肿瘤标志物水平明显低于对比组,差异有统计学意义(P<0.05)。结论采用甲磺酸阿帕替尼片对晚期非小细胞肺癌患者进行治疗可改善患者疾病控制情况,降低不良反应发生率,增加药物安全性,有效减轻患者疾病痛苦,具有进一步研究意义。Objective To analyze the clinical effect of Apatinib mesylate in the treatment of advanced non-small cell lung cancer(NSCLC). Methods 80 patients with advanced non-small cell lung cancer(NSCLC)from October,2015 to November,2017 were randomly selected and divided into two groups according to the order of admission with 40 patients in study group and control group.The study group were treated with Apatinib mesylate on the basis of control group,and the control group were treated with conventional chemotherapy. Results The total effective rate of the study group(87.50%)was significantly higher than that of the control group(65.00%). The safety of drugs in the study group was significantly higher than that in the control group,and the level of serum tumor markers in the study group was significantly lower than that in the control group(P< 0.05). There was a significant difference between the two groups. Conclusion Apatinib mesylate in patients with advanced non-small cell lung cancer can improve the disease control,reduce the incidence of adverse reactions,increase the safety of drugs,and effectively alleviate the pain of patients with non-small cell lung cancer. It has the significance of further study.

关 键 词：甲磺酸阿帕替尼片 晚期非小细胞肺癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]